6 results about "Normal flora" patented technology

This application provides a *Lactobacillus curvatureii* bacteriocin, its preparation method, and its application, relating to the field of biotechnology. The *Lactobacillus curvatureii* bacteriocin provided in this application is obtained through gene recombination expression and is a natural antibacterial ingredient with a broader antibacterial spectrum, low irritation, and long-lasting effect. Applying this *Lactobacillus curvatureii* bacteriocin to feminine hygiene products not only enhances the product's antibacterial effect but also helps repair and maintain the balance of the microecology, preventing disruption of normal flora, effectively maintaining the acidic environment of the intimate area, inhibiting the growth of pathogenic bacteria, and reducing the risk of infection. The feminine hygiene product of this application combines gentleness, high efficacy, and multifunctionality, while also focusing on microecological balance and mucosal repair to meet the higher needs of women's intimate care.

The invention discloses a preparation method of a monoclonal antibody for detecting trichophyton rubrum and application of the monoclonal antibody in fungal skin disease detection, and belongs to the field of biological medicine. The monoclonal antibody provided by the invention only has specific reaction with trichophyton rubrum, and has no cross reaction with common fungi such as trichophyton mentagrophytes, epidermophyton flocculent, candida albicans, malassezia and the like and normal flora of a human body, so that a false positive result is effectively avoided. Based on the double-antibody sandwich principle, the detection sensitivity can reach 200 pg / mL level, trace trichophyton rubrum in a clinical sample can be detected, and the positive rate is obviously higher than that of direct microscopic examination. The whole detection process can be completed within 15-20 min and is far faster than fungus culture for several weeks, a rapid diagnosis basis can be provided for doctors, and early treatment is facilitated. The kit provided by the invention has standardized operation steps, does not need complex instruments and special training, and is suitable for popularization and use in clinical laboratories of hospitals at all levels, outpatient clinics of dermatology and even basic medical institutions.

The invention provides an antibacterial peptide as well as a screening method and application thereof. On the first aspect, the invention provides the antibacterial peptide, and the amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO. 1. The antibacterial peptide has high specificity on staphylococcus aureus in a certain concentration range, has no inhibition effect on other common skin symbiotic bacteria such as staphylococcus epidermidis, staphylococcus vorus and propionibacterium acnes, can avoid damage to normal flora balance of a human body, reduces the risk of secondary infection, and has a good application prospect. The problem of flora imbalance caused by broad-spectrum killing of the existing antibacterial peptide is solved. In addition, the minimum inhibitory concentration on staphylococcus aureus is low, the obvious bacteriostatic effect can be achieved under the condition of lower dosage, and the medicine dosage and potential side effects are reduced. In addition, the compound is derived from human skin symbiotic microorganisms and has good biocompatibility with the human body, in-vitro cytotoxicity experiments prove that the effective antibacterial concentration of the compound has no obvious toxicity on human skin keratinocytes, and the safety of the compound is superior to that of chemically synthesized antibacterial molecules.

This invention belongs to the field of biomedical engineering and ophthalmic anti-infective therapy technology, specifically relating to a bacteriophage XP2 for treating Bacillus cereus endophthalmitis and its applications. Bacteriophage XP2 was deposited on November 18, 2025, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 47001. The bacteriophage provided by this invention exhibits high specificity in killing host bacteria, acting only against the host bacteria without disrupting normal flora or inducing widespread drug resistance. Simultaneously, the bacteriophage itself is non-toxic to normal retinal function and demonstrates excellent preservation of retinal function, even superior to vancomycin treatment, with a shorter onset time than vancomycin, approximately 30 minutes. This invention confirms the effectiveness of bacteriophage XP2 in directly reducing the bacterial load in Bacillus cereus-induced endophthalmitis and indirectly controlling inflammatory damage. By rapidly killing bacteria, XP2 minimizes neutrophil-induced inflammatory responses while protecting retinal structure and function.

The invention discloses an oral medicine containing sodium dehydroacetate, which is used for treating helicobacter pylori infection. In order to solve the problems of antibiotic resistance and gastrointestinal tract microecological disorder caused by the existing quadruple therapy, free molecules of the medicine disclosed by the invention under the gastric acid condition have strong lipophilicity, can efficiently penetrate through a gastric mucous layer and bacterial cell membranes, and can cause bacterial energy depletion death by blocking tricarboxylic acid cycle and energy metabolic centers such as succinate dehydrogenase. Animal experiments prove that the curative effect of reducing Hp colonization is equivalent to or even better than that of quadruple therapy. As a non-antibiotic bacteriostatic agent, the product has the advantages that drug resistance is not easy to generate due to multi-target action, normal intestinal flora is not damaged, flora imbalance and secondary infection are effectively avoided, and the safety is obviously improved.

The invention relates to the technical field of biology, and provides an ICU (Intensive Care Unit) multi-drug-resistant bacterium biological membrane removal system based on phage targeted delivery, which comprises a phage screening module for screening a specific phage for targeted lysis of ICU multi-drug-resistant bacteria; the targeted delivery module is used for accurately delivering the bacteriophage or the bacteriophage-drug compound into the biological membrane; the synergistic effect module is used for enhancing the penetrating and cracking effects of the bacteriophage on the biological membrane; the environment adaptation module is used for adjusting the acting environment parameters in the ICU scene; and the effect monitoring module is used for monitoring the biological membrane removal progress and the bacterial residue condition in real time. Drug-resistant bacteria are accurately cleared through specific bacteriophage and targeted delivery, and normal flora is guaranteed; the synergistic module breaks a biological membrane and assists in deep sterilization of bacteriophage; the activity of the bacteriophage is protected through environmental adaptation; and multi-dimensional monitoring and emergency regulation and control are adopted to prevent relapse, so that synergistic interaction and scene adaptability are achieved, the clearing efficiency is greatly improved, and the drug resistance risk is reduced.